Related Experiment Videos

Increased plasma HB-EGF associated with obesity and coronary artery disease

Satoru Matsumoto1, Ken Kishida, Iichiro Shimomura

  • 1Department of Internal Medicine and Molecular Science, Graduate School of Medicine, B5, Osaka University, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan.

Insights

Obesity increases vascular disease risk. This study shows increased heparin-binding epidermal growth factor (HB-EGF) from fat contributes to this link, suggesting HB-EGF is a key adipocytokine in the adipovascular axis.

Area of Science:

  • Cardiovascular Biology
  • Metabolic Syndrome Research
  • Adipose Tissue Biology

Background:

  • Obesity is linked to vascular disease, but the underlying mechanisms are unclear.
  • Adipose tissue secretes bioactive molecules called adipocytokines.
  • Heparin-binding epidermal growth factor (HB-EGF) is implicated in vascular smooth muscle cell migration and proliferation.

Purpose of the Study:

  • To investigate the role of HB-EGF in the relationship between obesity and vascular disease.
  • To determine if HB-EGF acts as an adipocytokine linking adipose tissue to the vasculature.

Main Methods:

  • Quantitative analysis of HB-EGF mRNA expression in human adipose tissue.
  • Assessment of HB-EGF mRNA levels in adipose tissue of obese mice.
  • Correlation analysis of plasma HB-EGF levels with body fat accumulation in humans.
  • Comparison of plasma HB-EGF levels in subjects with and without coronary artery disease.

Main Results:

  • HB-EGF mRNA is highly expressed in human adipose tissue.
  • Obesity in mice shows increased HB-EGF mRNA in fat tissue.
  • Plasma HB-EGF levels correlate positively with fat accumulation in humans.
  • Elevated plasma HB-EGF levels are observed in individuals with coronary artery disease, linked to fat accumulation.

Conclusions:

  • Increased plasma HB-EGF, originating from accumulated fat, contributes to the higher incidence of vascular disease in obesity.
  • HB-EGF is proposed as a novel adipocytokine that bridges the adipovascular axis.
  • Targeting HB-EGF may offer therapeutic strategies for obesity-related vascular complications.

Related Concept Videos